Lv1
60 积分 2023-08-31 加入
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
1个月前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
2个月前
已完结
Assessing the interactions between radiotherapy and antitumour immunity
3个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
4个月前
已完结
Twice-daily thoracic radiotherapy by intensity-modulated radiation therapy (IMRT) compared with simultaneous integrated boost IMRT (SIB-IMRT) with concurrent chemotherapy for patients with limited-stage small cell lung cancer. A propensity-score matched analysis
6个月前
已完结
Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes
7个月前
已完结
Current Controversies and Challenges in Non–Oncogene-Addicted Synchronous Oligometastatic Non–Small Cell Lung Cancer
7个月前
已完结
Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials
7个月前
已完结
Current Controversies and Challenges in Non–Oncogene-Addicted Synchronous Oligometastatic Non–Small Cell Lung Cancer
7个月前
已完结
Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and/or chemotherapy
8个月前
已完结
皖公网安备34019202002308
